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Objectives. This study was designed to examine the effects of a
beta-adrenergic blocking agent on the ischemic response to do-
butamine stress and to determine the degree to which these effects
can be abolished by the addition of atropine.
Background. Whether beta-blockade affects the sensitivity of
dobutamine stress echocardiography for the diagnosis of coronary
artery disease has been controversial.
Methods. In nine pigs, a left anterior descending coronary
artery stenosis was created to reduce ﬂow reserve (maximal/rest
ﬂow) to 1.1 to 1.9 without baseline regional wall motion abnor-
malities. This corresponded to a 50% to 90% diameter stenosis.
Wall thickening was measured using epicardial echocardiography.
Regional lactate production and coronary venous pH were moni-
tored from an adjacent cardiac vein. A standard protocol of
dobutamine stress echocardiography was ﬁrst performed. After
normalization of the ischemic abnormalities elicited with this
infusion, esmolol was infused at 50 g/kg body weight per min and
the dobutamine test was repeated, with 1.0 mg of atropine added
at the maximal dobutamine dose.
Results. Without esmolol, dobutamine stress induced myocar-
dial ischemia with a reduction in regional wall thickening and
lactate production in all nine pigs. Multiple regression analysis
revealed that coronary ﬂow per heartbeat (p < 0.01) and lactate
production (p < 0.05) independently correlated with regional wall
thickening during dobutamine stress. The beta-blocker signiﬁ-
cantly reduced heart rate and regional oxygen consumption and
altered the relation between coronary ﬂow per heartbeat and
regional wall thickening (p < 0.05) during dobutamine stress.
Esmolol prevented dobutamine-induced ischemia (lactate produc-
tion and wall motion abnormalities) in seven of nine pigs. The
addition of atropine induced lactate production and a reduction in
wall thickening in ﬁve of seven pigs in which ischemia had been
prevented by beta-blockade. However, lactate production was
higher and regional venous pH was lower with the baseline
dobutamine infusion than with that performed after esmolol with
atropine added at the maximal dobutamine dose (p < 0.05).
Conclusions. A correlation between regional wall thickening
and coronary ﬂow per heartbeat was demonstrated during base-
line dobutamine stress. Beta-blockade shifted this relation so that
dobutamine stress-induced myocardial ischemia was attenuated.
The mechanisms by which beta-blockade prevents dobutamine-
induced ischemia appeared to be mainly through decreases in
heart rate and rate of rise in left ventricular pressure, improve-
ment of regional coronary ﬂow per heartbeat and attenuation of
regional ischemic lactate production. Adding atropine in conven-
tional doses enhanced the ability of dobutamine stress to induce
myocardial ischemia but did not completely abolish the effects of
beta-blockade on either the severity of dobutamine-induced wall
thickening abnormalities or regional metabolic disturbances.
(J Am Coll Cardiol 1996;28:1866–76)
1996 by the American College of Cardiology
Dobutamine stress echocardiography has been widely applied
clinically for the noninvasive detection of coronary artery
disease (1–10). Dobutamine stimulates beta1 and alpha1 recep-
tors, resulting in positive inotropic and chronotropic effects.
These pharmacologic actions are dose dependent, with pre-
dominant increases in contractility and cardiac output at lower
doses and a progressive increase in heart rate at higher doses
(11–14). The rationale for the use of dobutamine for stress
testing is that it increases myocardial oxygen demand, thereby
inducing ischemia in patients with coronary artery disease
whose coronary ﬂow reserve is impaired or limited.
Patients referred for dobutamine stress testing are often
receiving beta-adrenergic blocking agents (3,15–17). With their
negative chronotropic and inotropic effects, beta-blockers may
prevent the ischemic response to dobutamine stress and may
adversely affect the ability of dobutamine stress to detect
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myocardial ischemia. However, the extent to which beta-
blockers prevent dobutamine-induced ischemic responses and
potentially affect the sensitivity of dobutamine stress for the
diagnosis of coronary artery disease in clinical studies has been
controversial (3,15,18,19). Despite the current controversy, it is
common clinical practice to stop beta-blockers temporarily 1 to
2 days or 4 half-lives of the agents before the dobutamine stress
test (17) or to add intravenous atropine (15,18) at the maximal
dose of dobutamine to increase heart rate. However, tempo-
rary discontinuation of beta-blockers may be hazardous, po-
tentially exacerbating previous symptoms of angina, or precip-
itating unstable angina, acute myocardial infarction and even
sudden death. Further, although adding atropine to the max-
imal dose of dobutamine has been shown to enhance the
sensitivity of dobutamine stress for detecting coronary artery
disease by increasing heart rate (15,18), the degree to which
the protective effect of a beta-blocker can be abolished by
adding atropine has not been well established.
Therefore, this study was designed to use a well-controlled
pig model with left anterior descending coronary artery (LAD)
stenosis to determine whether and through which mechanisms
beta-blockers prevent dobutamine-induced ischemia, and to
assess the degree to which the effects of beta-blockade can be
reversed by adding atropine during dobutamine stress echo-
cardiography. Because alterations in regional wall thickening
are frequently used to deﬁne the results of dobutamine stress
echocardiography, hemodynamic and biochemical factors re-
lated to the effect of dobutamine on wall thickening were ﬁrst
explored. Subsequently, the effects of beta-blockade on both
wall thickening and related variables were examined.
Methods
Animal preparation. The study protocol was approved by
the Committee on Animal Care at the Hartford Hospital, and
the “Position of the American Heart Association on Research
Animal Use” adopted by the Association in November 1984,
were followed. Nine pigs weighing 25 to 45 kg were studied. A
pig model of coronary artery stenosis was created as previously
described (20). Brieﬂy, general anesthesia was applied with
isoﬂurane (0.5% to 1.5%) and with an oxygen/nitrous oxide
mixture (30% to 50%/50% to 70%). The animals were intu-
bated and ventilated with adjustments to maintain normal
arterial blood gases. The isoﬂurane concentration was titrated
to inhibit the pain reﬂex without oversedation with anesthesia
to minimize the dose-dependent cardiodepressive effects and
to retain dynamic coronary autoregulation. Rectal tempera-
ture was maintained at 97 to 98 F by use of an electrically
heated surgical table and drapes. A femoral artery was cannu-
lated to monitor blood pressure and for blood samples.
Through left atrial cannulation, a 7F Millar catheter (Millar
Instruments, Inc.) was placed with a distal transducer in the
left ventricle and a proximal transducer in the left atrium for
measuring left ventricular and left atrial pressures and the rate
of rise in left ventricular pressure (LV dP/dt). A 3F coronary
perfusion catheter was introduced retrogradely through the
coronary sinus to the cardiac vein parallel to the stenotic LAD
segment and connected to a three-way stopcock for monitoring
oxygen content, lactate and pH. Full anticoagulation was
achieved and maintained with heparin, 200 IU/kg body weight
intravenously, followed by 30 IU/kg per hour. To prevent focal
coronary artery spasm due to surgical manipulations, 3%
lidocaine was intermittently applied focally at the proximal
LAD site at which the artery was manipulated. The proximal
LAD was dissected free to accept a coronary ﬂowmeter probe
(Transonic Inc), and a hydraulic cuff occluder was placed
around the LAD immediately distal to the ﬂowmeter. The
hyperemic reactions of the LAD at baseline and with stenosis
were determined by dividing the peak hyperemic coronary
blood ﬂow immediately after a brief occlusion of the vessel
(10 s) by the rest ﬂow. A graded LAD stenosis was created by
gradually ﬁlling the hydraulic occluder to reduce the coronary
ﬂow reserve to 1.0 to 2.0.
Experimental protocol. Baseline measurements of heart
rate, aortic pressure, left ventricular pressure, left atrial pres-
sure, regional coronary ﬂow, coronary venous lactate, pH and
oxygen content were obtained under stable conditions, deﬁned
as two consecutive measurements at 5-min intervals with a
difference of pH 0.02, coronary ﬂow 3 ml and mean blood
pressure 5 mm Hg. Stress echocardiography was performed
with incremental doses of dobutamine at 3-min intervals (5, 10,
20, 30 to 40 g/kg per min). The dobutamine stress test was
terminated when a signiﬁcant regional wall motion abnormal-
ity was noted by on-line visual evaluation. During dobutamine
only stress testing, each pig had 4 to 5 stage measurements
including baseline 1, yielding a total of 42 stage measurements.
The animal was then allowed to return to its baseline state with
normalization of heart rate, blood pressure and wall motion.
This process generally took 15 to 20 min. Subsequently,
esmolol was administered with a loading dose of 50 g/kg
followed by an infusion of 50 g/kg per min. The esmolol dose
was subsequently adjusted to decrease heart rate by 10 to 20
beats/min while maintaining a systolic blood pressure of
90 mm Hg or higher. Atropine, 0.8 to 1.0 mg, was added at the
maximal doses (30 g/kg per min for ﬁve pigs and 40 g/kg per
min for four pigs) of dobutamine. All measurements were
obtained at the end of each experimental stage. A total of 49
stages of measurements were obtained during dobutamine
stress testing with infusion of esmolol.
Echocardiographic measurements. Two-dimensional epicar-
dial echocardiography was performed using a mid-papillary
short-axis level recorded from the epicardial surface of the
right ventricle. Images were recorded on videotape for off-line
wall thickening analysis. The end-diastolic frame of the echo-
Abbreviations and Acronyms
LAD  left anterior descending coronary artery
LV dP/dt  rate of rise in left ventricular pressure
1867JACC Vol. 28, No. 7 CHEN ET AL.
December 1996:1866–76 EFFECTS OF BETA-BLOCKADE AND ATROPINE ON ISCHEMIA
cardiographic images was selected using the Q wave onset of
the electrocardiogram; the frame with the smallest left ventric-
ular cavity was deﬁned as end-systole. All premature heart-
beats and the ﬁrst postextrasystolic heartbeats were excluded.
The endocardial and epicardial borders of each frame were
manually traced according to the technique recommended by
the American Society of Echocardiography and digitized using
a commercially available computer system (Nova Microsonic).
The papillary muscles were excluded. Subsequently, the left
ventricle was divided into 100 equally spaced chords, and
regional wall thickening was quantiﬁed for each chord with a
centerline method as shown in Figure 1 (21). The chords were
then grouped into eight segments, starting from the junction of
the left ventricular inferior wall and the right ventricle as
follows: inferior ventricular septum, mid-septum, anterior sep-
tum, anterior wall, anterolateral wall, posterolateral wall,
posterior wall and inferior wall. The anterior septum and the
anterior wall were considered as the regions supplied by LAD
and the inferior wall was considered the control normal region.
The wall thickening from 12 chords in each region was
averaged for comparison.
Interobserver and intraobserver variability. All echocardio-
graphic measurements were performed by two observers who
had no knowledge of each others’ results. One observer
repeated measurements at least 3 weeks later. Interobserver
and intraobserver variability for measurements of regional wall
thickening was assessed using data from 36 hemodynamic
stages in nine animals.
Regional myocardial blood ﬂow measurements. Regional
myocardial blood ﬂow was measured with a cuff ﬂow probe
connected to a transonic ﬂowmeter (Transonic Inc.). The
ﬂowmeter was calibrated against a known rate of blood ﬂow to
ensure the accuracy of the measurements. After completion of
the experiment, the pigs were killed and their hearts were
harvested. Methylene blue was injected into the LAD to stain
the myocardium supplied by the stenotic vessel. The stained
tissue was dissected and weighed to determine the regional
myocardial mass perfused by the stenotic coronary artery.
Regional coronary blood ﬂow was expressed as milliliters per
minute per gram of wet tissue.
Regional myocardial metabolic measurements. To inhibit
glycolysis, arterial and coronary venous blood samples were
obtained anaerobically in cold, dry syringes containing heparin
ﬂuoride. The samples were divided for blood gas and lactate
analyses, stored on ice and processed immediately after the
experiment. Blood gases were analyzed in duplicate, and the
values were averaged. Plasma for lactate content was depro-
teinated with perchloric acid, neutralized with potassium hy-
droxide and imidazole buffer and then analyzed using the
enzymatic method. Regional myocardial oxygen consumption
was calculated by subtracting the coronary venous oxygen
content from the arterial oxygen content and then multiplying
the regional transmural blood ﬂow supplied by the LAD.
Lactate consumption/production was calculated by subtracting
the coronary venous lactate from arterial lactate and then
multiplying the regional transmural blood ﬂow.
Statistical analysis. All data were expressed as mean
value  SD. Repeated measures one-way analysis of variance
and the Tukey-Honestly test were used to compare parametric
data. Least squares linear regression was used to test the
correlation between parametric variables. The difference be-
tween correlations was examined by one-way analysis of co-
variance. Multiple stepwise regression was applied to evaluate
independent variables that were related to regional wall thick-
ening during dobutamine stress. The variables included heart
rate, mean blood pressure, rate-pressure product, regional
coronary blood ﬂow per minute, regional coronary blood ﬂow
per heartbeat and regional lactate production or extraction in
42 stages of measurements during dobutamine stress test. To
account for the factor of multiple observations (4 to 5 stages)
in each of nine pigs, we considered the multiple stages in each
pig as an additional independent variable for the multiple
regression analysis. Speciﬁcally, we averaged the values of wall
thickening (y) from multiple observations for each pig, yielding
a total of nine different mean values in nine pigs. The averaged
value for each pig was then used for all stages in each pig and
was treated as an additional independent variable (x) added to
the other six independent variables (heart rate, regional coro-
nary blood ﬂow per minute, coronary blood ﬂow per heartbeat,
blood pressure, rate-pressure product, lactate extraction) for
multiple stepwise regression analysis with wall thickenings in
each stage as a dependent variable. A value of p  0.05 was
considered statistically signiﬁcant.
Figure 1. An example of the centerline method applied in this study.
The left ventricle was equally divided into 100 chords. The ﬁrst chord
started from the right/left ventricular junction. Chord nos. 1–12, 13–25,
26–37, 38–50, 51–62, 63–75, 76–87 and 88–100 represent the infero-
septum (IS), mid-septum (MS), anteroseptum (AS), anterior wall
(AT), anterolateral wall (AL), posterolateral wall (PL), posterior wall
(PT) and inferior wall (IF), respectively. The dashed lines indicate
2 SD of the mean normal value from nine pigs at baseline without
coronary stenosis. An example of wall thickening at baseline in a pig
with a left anterior descending coronary artery stenosis is denoted by
the solid line. The bold solid line indicates wall thickening in the same
pig at peak dobutamine stress. Note that a signiﬁcant deterioration of
wall thickening in the anteroseptal and anterior regions indicates a
positive dobutamine stress test.
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Table 1. Responses of Hemodynamic Variables, Regional Myocardial Function, Perfusion and Metabolism to Incremental Doses of Dobutamine at Each Stage With or Without Esmolol
and Atropine
Baseline Stenosis
Dobutamine
5 mg 10 mg 20 mg Max. Max.  A
HR (beats/min)
No esmolol 103  9 115  15 140  21 158  23 181  18 191  16
Esmolol 94  12* 114  15† 118  13† 124  12† 139  10† 154  11‡§
BPs (mm Hg)
No esmolol 106  10 109  15 120  17 116  21 108  16 104  20
Esmolol 99  12 109  19 111  23 114  18 114  18 114  16
RPP
No esmolol 11,043.7  1802.7 12,931.9  2203.9 16,186.7  1,372.5 18,515.0  2,551.7 19,489.0  3,039.8 20,065.4  3,046.1
Esmolol 10,457.3  1,885.9* 12,340.9  2,131.5† 13,044.7  2,906.1† 14,064.1  2,281.0† 14,920.1  3,072.2† 17,069.0  3,076.8‡§
LV dP/dt (mm Hg/s)
No esmolol 1,433.7  137.3 1,336.3  125.0 2,701.3  290.8 3,031.7  453.7 3,194.7  422.5 3,362.3  388.6
Esmolol 1,025.7  164.4* 1,655.7  319.1† 2,081.0  562.2† 2,308.7  550.7† 2,415.3  497.5† 2,423.3  487.3
CBF (ml/g per min)
No esmolol 1.12  0.14 1.07  0.12 1.37  0.19 1.47  0.25 1.37  0.28 1.32  0.17
Esmolol 0.86  0.14† 1.01  0.18† 1.15  0.22† 1.25  0.27 1.34  0.26 1.26  0.21
CF/b (103 ml/g)
No esmolol 10.8  0.7 9.8  1.7 11.0  2.0 9.6  2.5 7.7  2.0 6.9  1.0
Esmolol 8.2  1.2* 8.9  1.7† 9.7  2.6 10.2  2.6† 9.7  2.2† 8.6  1.5§
WTnl (%)
No esmolol 45.0  2.44 46.8  3.9 63.8  5.7 71.4  5.8 77.2  5.5 83.1  4.5
Esmolol 43.4  1.5† 55.4  5.0† 61.9  3.7† 68.3  4.6† 70.4  3.9† 70.6  3.5
WTis (%)
No esmolol 42.5  3.3 38.9  3.4 47.8  6.3 46.2  12.1 34.5  9.0 26.1  4.5
Esmolol 36.5  3.3* 43.0  3.9* 45.1  4.0 50.1  6.0† 44.2  5.9† 34.4  5.0¶
MV˙O2 (ml/100 per min)
No esmolol 5.76  1.49 4.78  1.31 6.89  1.23 8.04  1.81 8.51  2.24 7.65  3.31
Esmolol 3.79  1.88* 4.13  1.38† 4.88  1.93† 5.12  2.27* 5.28  1.50* 6.01  2.57‡
Lacp (mol/g per min)
No esmolol 0.73  0.29 0.36  0.24 0.49  0.40 0.05  1.14 0.29  1.51 0.96  1.93
Esmolol 0.26  0.22 0.28  0.30 0.43  0.48 0.32  0.41† 0.04  0.66† 0.17  0.55
Hcv (pH)
No esmolol 7.41  0.05 7.38  0.04 7.37  0.02 7.34  0.06 7.32  0.09 7.26  0.04
Esmolol 7.38  0.03 7.38  0.02 7.36  0.03 7.35  0.07† 7.34  0.03† 7.31  0.05‡
*p  0.05. †p  0.01 for no esmolol versus esmolol. ‡p  0.05. §p  0.05. p  0.01 for no esmolol versus esmolol plus atropine at maximal dose of dobutamine. ¶p  0.01 for esmolol versus esmolol plus atropine at
maximal dose of dobutamine. Dated are presented as mean value  SD. A  atropine; BPs  systolic blood pressure; CBF  regional coronary blood ﬂow; CF/b  coronary ﬂow per beat; Dob  dobutamine; Hcv 
regional coronary venous hydrogen ion; HR  heart rate; Lacp  regional lactate production; LV dP/dt  rate of rise in left ventricular pressure; MVOV˙2  regional myocardial oxygen consumption; RPP  rate-pressure
product; WTis  wall thickening at ischemic area; WTnl  wall thickening at normal area.
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Results
Coronary blood ﬂow reserve at baseline was 3.56 0.42 and
was reduced to 1.48  0.26 (range 1.1 to 1.9) with LAD
stenosis. Table 1 shows the alterations of hemodynamic vari-
ables, regional coronary blood ﬂow, regional oxygen consump-
tion, regional metabolism and regional myocardial function at
each experimental stage, including control baseline, baseline
after creation of LAD stenosis (stenosis baseline) and LAD
stenosis with incremental doses of dobutamine without esmo-
lol, with esmolol and with esmolol plus atropine.
Hemodynamic variables, regional coronary ﬂow and oxygen
consumption responses with and without beta-blocker during
dobutamine stress (Table 1). Baseline. With intravenous es-
molol, heart rate decreased signiﬁcantly from 115  15 beats/
min at baseline to 94  12 beats/minute (p  0.05) after
esmolol, as did dP/dt (from 1,336.3  125.0 mm Hg/min at
baseline to 1,035.7  164.4 mm Hg/min with esmolol,
p 0.05). Regional coronary blood ﬂow decreased (Table 1, p
0.01). Coronary ﬂow per heartbeat decreased (Table 1, p 0.05),
as did regional myocardial oxygen consumption (Table 1, p 
0.01). Systolic blood pressure remained unchanged (p  0.05).
Dobutamine stress. With incremental doses of dobutamine
without esmolol, there were signiﬁcant increases in heart rate,
dP/dt and regional coronary blood ﬂow per minute (Table 1).
A signiﬁcant decrease in regional coronary ﬂow per heartbeat
was observed at doses of dobutamine 20 g/kg per min.
Systolic blood pressure increased slightly at lower doses of
dobutamine (5 to 10 g/kg per min), plateaued and subse-
quently slightly decreased at the maximal doses of dobutamine
infusion.
Dobutamine stress with esmolol. With esmolol, incremental
doses of dobutamine signiﬁcantly increased heart rate, dP/dt,
coronary blood ﬂow and systolic blood pressure. However, at
comparable stages, increases in heart rate and dP/dt with
esmolol were not as great as without esmolol (Table 1). With
esmolol, the maximal heart rate at maximal doses of dobut-
amine was 140  10 beats/min and dP/dt was 2,415  497 mm
Hg/s, signiﬁcantly less than those without esmolol (Table 1). At
maximal doses of dobutamine, the regional coronary blood
ﬂow with esmolol was not different from the ﬂow without
esmolol. The coronary ﬂow per heartbeat was, however, sig-
niﬁcantly higher in the stages with esmolol than the ﬂow per
heartbeat without esmolol (9.7  2.2 vs. 6.9  1.0 ml/beat per
1,000 myocardium, p  0.01).
Effect of adding atropine. In the stages with esmolol, adding
atropine at the maximal dose of dobutamine signiﬁcantly
increased heart rate (156 8 beats/min), but not to the degree
achieved by dobutamine alone in non–beta-blocked stages
(191  16 beats/min, p  0.05). dP/dt and regional coronary
blood ﬂow were not signiﬁcantly affected by adding atropine
(Table 1, p  NS for each). Coronary ﬂow per heartbeat was,
however, reduced by adding atropine, but not to the degree
achieved by dobutamine alone in non–beta-blocked stages
(Table 1, p  0.05). Atropine increased regional myocardial
oxygen consumption from 5.28 1.5 to 6.01 2.57 ml/min per
100 g myocardium (p  0.05). However, oxygen consumption
after atropine was still signiﬁcantly less than the level achieved
by dobutamine alone in non–beta-blocked stages (6.01  2.57
vs. 7.65  3.31 ml/min per 100 g myocardium, p  0.05).
Alteration of regional wall thickening during dobutamine
stress. Interobserver and intraobserver variability. The differ-
ence in measurements of regional wall thickening between two
observers (C.L. and M.L.) was 2.3  5.4%. The difference in
repeated measurements of wall thickening from the same
observer was 1.9  2.4% for C.L. The measurement error
according to Bland and Altman (22) was 6.7% for the same
observer.
Baseline wall thickening with and without esmolol. Normal
ranges of wall thickening for each segment were established
from baseline echocardiograms in nine pigs without coronary
stenosis (Fig. 1). There was no signiﬁcant change in regional
wall thickening after the creation of the LAD stenosis, with
values remaining within normal limits in all pigs (Fig. 2A).
Intravenous esmolol decreased wall thickening from 38.9 
3.4% to 36.5  3.3%, p  0.05) in the regions with LAD
stenosis as well as in the normal control regions (from 43.4 
1.5% to 36.5  3.3%, p  0.05).
Wall thickening alterations during incremental doses of dobut-
amine infusion. Without esmolol, wall thickening in regions
supplied by the stenotic LAD demonstrated a typical biphasic
response, increasing at lower doses of dobutamine, peaking at
about 10 g/kg per min with a subsequent decrease at higher
doses (Table 1). In control regions (the inferior wall), wall
thickening increased signiﬁcantly with low doses of dobut-
amine with no signiﬁcant change after 20 g/kg per min. In
contrast, with esmolol, regional wall thickening in the segments
supplied by the stenotic LAD continuously increased with
incremental doses of dobutamine infusion in most pigs (Table
1, Fig. 2B).
Adding atropine to maximal doses of dobutamine. In the
beta-blocked stages, the addition of atropine at maximal doses
of dobutamine resulted in a decrease in wall thickening from
44.2 5.9% to 34.4 5.0% (p 0.01) in the LAD regions, but
not to the level achieved by dobutamine alone in non–beta-
blocked stages (26.1  3.0%, p  0.05) (Table 1, Fig. 2A, B).
In control regions, wall thickening was not signiﬁcantly
changed by atropine.
If regional myocardial ischemia or a positive dobutamine
stress result was deﬁned as unchanged (alteration of less than
the measurement error of 6.7%) or decreased wall thickening
during dobutamine stress, all nine pigs had positive test results
in the non–beta-blocked state (Fig. 2A and 3). Esmolol
prevented the reduction of wall thickening induced by dobut-
amine in seven of nine pigs (Fig. 2B and 4). With the
subsequent addition of atropine, wall thickening decreased in
seven of nine pigs (Fig. 2B and 4); of these, two of nine pigs
showed a further reduction beyond that elicited by dobutamine
alone, whereas ﬁve of nine pigs had reduced wall thickening
only when atropine was added. The remaining two pigs showed
no reduction in wall thickening at maximal doses of dobut-
amine with or without atropine (Fig. 2B).
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Myocardial metabolic alterations with and without esmolol
during dobutamine stress. Baseline. Regional myocardial lac-
tate consumption after beta-blockade was not different from
that in the non–beta-blocked state (p  NS). Similarly,
regional coronary venous pH was similar before the creation of
the stenosis and after LAD stenosis both with and without
esmolol (p  NS). Regional myocardial oxygen consumption
decreased signiﬁcantly (p  0.05) after esmolol (Table 1).
Dobutamine stress test. In non–beta-blocked stages, incre-
mental doses of dobutamine increased regional lactate and
reduced pH. At the maximal dose of dobutamine, regional
lactate consumption (positive value) converted to lactate pro-
duction (negative value in Table 1). In contrast, after beta-
blockade, in seven of nine pigs regional lactate consumption
was signiﬁcantly reduced but did not convert to lactate pro-
duction at maximal doses of dobutamine (Table 1).
Effect of adding atropine. Adding atropine at the peak dose
of dobutamine increased lactate production (Table 1, p 
0.05), although regional pH fell (Table 1, p  0.05). However,
neither variable reached the levels achieved at the correspond-
ing stage without esmolol (Table 1, p  0.05 for each).
Factors related to regional wall thickening during dobut-
amine stress. Heart rate (r  0.73, p  0.01), rate-pressure
product (r  0.70, p  0.01), regional coronary blood ﬂow
(ml/g per min) (r  0.60, p  0.05), coronary blood ﬂow per
heartbeat (r  0.81, p  0.01), myocardial lactate production
(r  0.64, p  0.05) and myocardial oxygen consumption (r 
0.49, p  0.05) all correlated signiﬁcantly with wall thickening
in the region supplied by the LAD during incremental dobut-
amine infusion without esmolol or atropine. However, multiple
stepwise regression analysis revealed that only coronary ﬂow
per heartbeat (ml/g per 103, x1) and regional arterial-coronary
lactate extraction (%, x2) were independent variables that
predicted regional wall thickening during dobutamine stress
(multiple R  0.835, p  0.001, y  3.6x1  0.7x2  7.9). The
stepwise regression procedure did not select the averaged wall
thickening for each pig as a statistically signiﬁcant independent
variable (p  0.17, partial r  0.23). When we forced this
variable into the ﬁnal equation, multiple R2 was 0.6998 (r 
0.837, F  22.46, p  0.001) and was not different from the R2
of 0.698 (r  0.835, F  32, p  0.001) without this variable in
Figure 2. A, Changes in regional wall thickening supplied by a stenotic
(ST) left anterior descending coronary artery from baseline to maximal
dobutamine doses (Max. D). B, Improved regional wall thickening in
the left anterior descending coronary artery regions with esmolol at
maximal doses of dobutamine (Max. D  E) compared with baseline
values. Note that regional wall thickening decreased by adding atro-
pine (Max. D E A). The mean value (SD, solid circle with bars)
of wall thickening was provided for each stage.
Figure 3. A two-dimensional echocardiogram with LAD stenosis
before dobutamine stress, and at a dobutamine (Dob) dose of 20 g/kg
per min. Note that the anteroseptal and anterior wall thickening was
normal at baseline with LAD stenosis. A signiﬁcant reduction in wall
thickening of the anterior and anteroseptal regions was induced at the
dobutamine dose of 20 g/kg per min. ED  end-diastolic frame;
ES  end-systolic frame; S  septum; P  posterior wall.
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the ﬁnal regression equation including only two statistically
signiﬁcant independent variables (coronary ﬂow per heartbeat
and lactate production). Therefore, the fact that there were
multiple observations in each pig did not affect the results of
the multiple regression analysis. Esmolol signiﬁcantly altered
the slope of the regression line between wall thickening and
coronary ﬂow per heartbeat (Fig. 5). The slope was ﬂatter with
esmolol than without esmolol, indicating that for an identical
level of regional coronary blood ﬂow and heart rate, regional
wall thickening would be greater with esmolol if the coronary
ﬂow per heartbeat is at the lower range (usually at high doses
of dobutamine), but wall thickening would be less with esmolol
if the coronary ﬂow per heartbeat is at the higher range
(usually at low doses of dobutamine).
The degree of LAD stenosis and the degree of coronary
blood ﬂow reserve (1.48  0.26) correlated signiﬁcantly with a
reduction in regional wall thickening at the maximal doses of
dobutamine with or without esmolol (Fig. 6). However, esmo-
lol shifted the slope of the regression line between a reduction
in wall thickening and coronary blood ﬂow reserve (p  0.01).
With esmolol infusion, in seven of nine pigs in which dobut-
amine stress did not induce a reduction in regional wall
thickening, coronary blood ﬂow reserve (1.53 0.21) appeared
higher than the ﬂow reserve (1.17 0.14) in the remaining two
pigs with positive testing. By adding atropine, ﬁve of seven pigs
with a negative dobutamine stress test in the presence of
beta-blockade became positive. These ﬁve pigs appeared to
have a lower coronary blood ﬂow reserve (1.45  0.22) than
Figure 4. Two-dimensional echocardiographic images in
the same pig as in Figure 2 with LAD stenosis with esmolol
(ES) infusion, during dobutamine (Dob) doses of 20 and
30 g/kg per min and adding atropine (A). Note that wall
thickening at stenosis baseline was within normal limits; at
20 g/kg per min of dobutamine, wall thickening increased
in all regions. Wall thickening slightly decreased at 30 g/kg
per min from wall thickening at 20 g/kg per min in the
anterior and anteroseptal regions. However, at the maximal
dose of dobutamine (30 g/kg per min), the regional wall
thickening in the LAD regions was slightly better than that
at baseline, indicating a negative stress test. Adding atropine
induced a signiﬁcant reduction in wall thickening in the
anterior and anteroseptal regions. Abbreviations as in Fig-
ure 3.
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the other two animals with tests that remained negative
(1.79  0.11).
Discussion
In this study, beta-blockade blunted the ischemic response
to dobutamine stress, an effect only partially eliminated by
atropine. Importantly, this study also provided hemodynamic
and biochemical correlates of this phenomenon and demon-
strated that beta-blockade causes a shift in the relation be-
tween regional wall thickening and coronary ﬂow per heart-
beat.
Dobutamine stress in the non–beta-blocked state. This
study conﬁrmed the results of previous clinical (3,9) and
experimental studies (20), in that incremental doses of dobut-
amine induce a characteristic biphasic pattern in wall thicken-
ing in regions supplied by signiﬁcant coronary artery stenosis
but without baseline regional wall motion abnormalities. This
consisted of an initial increase in wall thickening at low doses
of dobutamine, with subsequent signiﬁcant decreases in wall
thickening to or below baseline values at higher doses. In
contrast, in normally perfused regions, regional wall thickening
increased signiﬁcantly at low doses of dobutamine with either
further increases or no change in wall thickening at high doses.
This study further demonstrated that during dobutamine
stress, the severity of the ﬂow limitation (impaired ﬂow
reserve), heart rate and myocardial ischemic metabolic distur-
bances (lactate production and acidosis) interactively inﬂu-
enced alterations in wall thickening in areas supplied by a
stenotic LAD.
Dobutamine stress in beta-blockade. In most animals,
beta-blockade attenuated or completely prevented the isch-
emic response to dobutamine stress. This effect may be medi-
ated through decreases in heart rate, rate-pressure product,
dP/dt and regional myocardial oxygen consumption at peak
dobutamine doses. Because total transmural regional coronary
blood ﬂow per minute was not signiﬁcantly altered by intrave-
nous esmolol during dobutamine stress, the slower heart rate
with esmolol during dobutamine stress resulted in a relative
increase in coronary ﬂow per heartbeat. The increase in
coronary blood ﬂow per heartbeat and the decrease in regional
myocardial oxygen consumption increased regional wall thick-
Figure 6. Correlation between coronary blood ﬂow
reserve and changes (%) in wall thickening at the
maximal dose of dobutamine, with the addition of
esmolol or esmolol plus atropine. Note that there is
a signiﬁcant correlation for each setting but with
different slopes. Regression equation was y 
51.6x  105, r  0.69, p  0.01 for dobutamine
alone; y  68.5x  71.9, r  0.73, p  0.001 for
dobutamine stress with esmolol; and y  58.8x 
88.8, r  0.82, p  0.001 for adding atropine at peak
dobutamine stress with esmolol.
Figure 5. Correlations between coronary blood ﬂow per heartbeat
(ml/beat per 1,000 g myocardium) and regional wall thickening with
and without esmolol and atropine during incremental doses of dobut-
amine infusion. Note that esmolol and atropine altered the regression
slope.
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ening and prevented an ischemic response during dobutamine
stress.
The degree to which beta-blockers prevented the ischemic
response during dobutamine stress appeared to be related to
the degree of reduction in coronary blood ﬂow reserve and the
severity of the coronary stenosis. In two of nine pigs with more
severe coronary stenosis (coronary reserves of 1.07 and 1.27),
esmolol did not prevent dobutamine-induced myocardial isch-
emia, whereas in seven of nine pigs with higher coronary ﬂow
reserves of 1.3 to 1.9 (1.53  0.21), beta-blockade prevented
dobutamine-induced ischemia.
Intravenous atropine added to the maximal dobutamine
doses partially reversed the beta-blockade effect and induced
ischemia in ﬁve of seven pigs in which ischemic response was
prevented by esmolol. However, in two of seven pigs with less
severely impaired coronary blood ﬂow reserves of 1.7 and 1.9,
adding atropine did not induce abnormal regional wall thick-
ening or ischemic lactate production. Correspondingly, al-
though atropine signiﬁcantly increased heart rate, it did not
completely abolish the effects of beta-blockade on heart rate,
dP/dt, regional wall thickening and lactate production in this
study.
Determinants of regional wall thickening during dobut-
amine stress. Because changes in regional wall thickening are
frequently used to deﬁne the results of dobutamine stress
echocardiography, this study evaluated a number of variables
that potentially inﬂuence regional wall thickening. Multiple
stepwise regression analysis indicated that coronary blood ﬂow
per heartbeat (regional coronary ﬂow/heart rate) and myocar-
dial lactate extraction were independently correlated with
regional wall thickening, whereas systolic or mean blood
pressure and the product of heart rate and systolic blood
pressure were not. The absence of a relation between wall
thickening and blood pressure may be explained by two
potentially opposing effects. Thus, increases in blood pressure
increase myocardial oxygen consumption and afterload, which
may reduce regional wall thickening if coronary blood ﬂow
supply (reserve) is limited. However, increases in blood pres-
sure also increase coronary perfusion pressure (mean aortic
pressure  left ventricular diastolic pressure), and thus in-
crease coronary blood ﬂow (23,24). This increase in coronary
blood ﬂow may prevent ischemia and improve regional wall
thickening by improving oxygen supply if the increase in
oxygen demand does not exceed the increase in regional
coronary blood ﬂow.
The correlation between regional coronary blood ﬂow per
heartbeat and regional wall thickening was slightly altered by
beta-blockade and by adding atropine (signiﬁcant difference in
slopes, p  0.01 by analysis of covariance). Beta-blockade
decreased heart rate during dobutamine stress. The decrease
in heart rate resulted in an increase in coronary blood ﬂow per
heartbeat because total regional coronary ﬂow was unchanged.
As shown in Figure 5, it would be predicted that an increase in
coronary blood ﬂow per heartbeat would increase regional wall
thickening and preventing dobutamine-induced reduction in
wall thickening. It would be expected that adding atropine, by
reducing coronary blood ﬂow per heartbeat, would decrease
regional wall thickening and produce an ischemic dobutamine
stress response.
Coronary blood ﬂow reserve correlated signiﬁcantly with
the percent change in wall thickening at the maximal doses of
dobutamine, indicating a quantitative relation between re-
gional wall thickening and the severity of the coronary artery
stenosis. The relation was shifted upward by esmolol (Fig. 6).
Thus, with identical coronary blood ﬂow reserves, there will be
greater wall thickening at peak dobutamine with esmolol than
without it, potentially resulting in a negative test result.
Atropine only partially reversed the effect of beta-blockade on
the relation between coronary blood ﬂow reserve and regional
wall thickening at the maximal doses of dobutamine.
Previous studies. Although the ability of beta-blockade to
prevent myocardial ischemia either at rest or during exercise
has been well established (25,26), there has been controversy
as to whether beta-blockade prevents the induction of regional
left ventricular wall motion abnormalities during dobutamine
stress (3,15,18,19). In their clinical studies, Sawada et al. (3)
and Marcovitz and Armstrong (19) reported that beta-
blockade did not signiﬁcantly inﬂuence the sensitivity of do-
butamine stress echocardiography for detecting signiﬁcant
coronary stenosis. In contrast, in a recent prospective study of
25 patients on and off beta-blockers, Fioretti et al. (18) showed
that beta-blockade blunted the chronotropic effect of dobut-
amine and signiﬁcantly reduced the ability of dobutamine
stress to induce echocardiographic markers of myocardial
ischemia. They showed that by adding atropine to the peak
dose of dobutamine, heart rate was further increased and
echocardiographically deﬁned dobutamine-induced myocar-
dial ischemia was enhanced (18). However, conﬁrmation of the
presence or absence of coronary artery stenosis by coronary
angiography was performed in only 15 patients in the study by
Fioretti et al. Thus, in addition to the relatively small number
of patients studied, selection bias relative to the severity and
extent of coronary stenosis may have contributed to discrepant
ﬁndings in these clinical studies. In this animal study, all such
confounding variables are well deﬁned and tightly controlled.
Study limitations. There is no ideal system to quantify
regional wall thickening (27). However, the modiﬁed center-
line method used in this study is well accepted. Further,
measurements were performed by two experienced echocar-
diographers and the values were averaged, minimizing poten-
tial observer bias. In our animal model, the quality of epicar-
dial echocardiographic images was excellent, and thus clear
delineation of epicardial and endocardial borders was possible.
This method may not be applicable for clinical transthoracic
echocardiographic images. However, images from transesoph-
ageal echocardiography could be comparable to the epicardial
images, and quantiﬁcation of wall thickening could be applied
(28).
Four pigs in the initial phase of this study did not receive a
maximal dose of 40 g/kg per min when atropine was added.
The dose of 30 g/kg per min was deﬁned as the maximal dose
of dobutamine in the initial phase of this study and was based
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on the fact that all regional wall motion abnormalities were
induced by a dobutamine dose 30 g/kg per min without
beta-blockade effects in this study. In the second phase of this
study, a maximal dobutamine dose of 40 g/kg per min was
used if there was no regional wall motion abnormalities with
esmolol. Even in this subgroup, only two of four pigs had a
positive dobutamine stress test.
Results from this model with single-vessel disease may not
be applicable in the setting of multivessel disease. Further,
although the effects of anesthesia were minimized in this study,
the hemodynamic responses observed could be different in the
awake state. However, trends of changes in heart rate and
blood pressure in this study were similar to those reported in
awake humans during dobutamine stress either with or without
esmolol and atropine (15,18).
Despite the above limitations, this study has its unique
advantages. In this model, simultaneous measurements of
regional LAD ﬂow, myocardial oxygen consumption and met-
abolic variables (lactate and pH) as well as wall thickening
were feasible, and the high quality of the epicardial echocar-
diographic images enabled quantitative analysis of changes in
regional wall thickening during dobutamine stress. Myocardial
ischemia deﬁned by a reduction in regional wall thickening
could therefore be correlated with hemodynamic and regional
metabolic variables.
Clinical implications. This study has important clinical
implications. A quantitative relation was demonstrated be-
tween coronary blood ﬂow reserve or coronary blood ﬂow per
heartbeat and regional wall thickening and myocardial isch-
emic lactate production, indicating that dobutamine echocar-
diography provides not only qualitative but, to some extent,
quantitative information on stress-induced myocardial isch-
emia.
Whether heart rate or the rate-pressure product should be
used to quantitate or determine the adequacy of dobutamine
stress has not been systematically studied. This study showed
that heart rate or regional coronary blood ﬂow per heartbeat
correlated signiﬁcantly with changes in regional wall thicken-
ing, although blood pressure did not. The rate-pressure prod-
uct did not improve the correlation between regional wall
thickening and coronary blood ﬂow per heartbeat. Therefore,
the results of this study suggest that during dobutamine stress,
heart rate rather than the rate-pressure product should be used
to monitor and quantitate the level of stress.
This study showed that beta-blockade prevented dobutamine-
induced myocardial ischemia using either an echocardio-
graphic (reduced wall thickening) or metabolic (regional
myocardial anaerobic metabolism) criterion. Therefore, dobut-
amine stress echocardiography should be interpreted with
caution in patients taking beta-blockers, especially in patients
who have an inadequate increase in heart rate during incre-
mental dobutamine infusion. Even when an adequate heart
rate response is achieved by adding atropine, beta-blockade
can prevent signiﬁcant reductions in wall thickening or isch-
emic lactate production in the setting of stenoses with mildly
impaired coronary blood ﬂow reserve. However, in this
study, by adding atropine, dobutamine stress echocardiography
detected the majority (seven of nine pigs) of signiﬁcant LAD
stenosis of ﬂow reserve 1.07 to 1.78), corresponding to 50% to
90% diameter stenosis in this study (23,24). Two pigs that
continued to have negative results, despite adding atropine,
had a less severe stenosis (ﬂow reserves of 1.7 and 1.9,
corresponding to 50% to 70% diameter stenosis). Therefore,
this study supports the clinical practice of adding atropine to
dobutamine stress in patients who are taking beta-blockers.
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